Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

HIV-1 Vif: Multiple ways to outsmart the body’s defences?

17.09.2004


The way that HIV disables the body’s natural defences against retroviruses is not as well understood as recent studies suggest, according to new research published in the Open Access journal Retrovirology. Klaus Strebel and his colleagues from NIH found that the HIV encoded Vif protein does not need to destroy the enzyme APOBEC3G within infected cells to disable it. This latest finding has serious implications for the design of antivirals to fight HIV.

APOBEC3G is one of the most recently identified ways that the body fights off unwanted attacks by retroviruses such as HIV. APOBEC3G is a cellular enzyme with the ability to chemically modify viral genomes and to change their genetic code. The changes to the HIV genome effectively neutralize it and prevent it from spreading to uninfected cells.

Recent research has shown that HIV has found a way to outsmart the body’s attempts to prevent it from replicating. HIV’s viral infectivity factor, or Vif, can prevent the packaging of APOBEC3G into the virus particles, stopping the enzyme from damaging the viral genome. The most popular current working model proposes that Vif does this by destroying APOBEC3G in infected cells.



Strebel and colleagues from the National Institutes of Health analyzed the coexpression of Vif and APOBEC3G in single-cells. They found that Vif can inactivate APOBEC3G without eliminating it from the virus producing cells. In their system, APOBEC3G was expressed at high levels even in the presence of Vif; yet, viruses produced in the presence of Vif were fully infectious.

These findings have important implications as they question the current working model proposing the efficient elimination of APOBEC3G from Vif-expressing cells. The authors do not question the validity of previously published data reporting on the destruction of APOBEC3G by Vif. Instead, they claim that destruction of APOBEC3G by Vif is not essential for the virus to multiply, and propose that the HIV Vif protein may have acquired the ability to target APOBEC3G on multiple levels to ensure that this protein is not packaged into viral particles. Understanding the exact mechanism of how Vif inhibits APOBEC3G will be essential for the design of antivirals targeting Vif.

Grace Baynes | Press BioMed Central
Further information:
http://www.retrovirology.com/content/1/1/27
http://www.biomedcentral.com
http://www.niaid.nih.gov

More articles from Life Sciences:

nachricht Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH

nachricht Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>